Business
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S. and Europe, leading to nine regulatory approvals. “We are thrilled to welcome Dr. Borgman, whose expertise in developing targeted oncology drugs, makes her an ideal addition to our executive team,” said Bill Newell, Sutro’s Chief Executive Officer. “With our plans to initiate our Phase 2/3 registration-directed study of luvelta in patients with advanced ovarian cancer in the second quarter of this year, we look forward to Anne’s immediate contributions to our development efforts. With a long-standing track record of successful drug development experience spanning from early stages to regulatory approvals, we are confident that Anne will also play an important role in the continued expansion of our pipeline.” “I was drawn to Sutro because of its promising pipeline, together with multiple product candidates currently in clinical study. In addition, Sutro has executed meaningful relationships with global pharmaceutical partners,” said Dr. Borgman. “I believe Sutro is well-positioned to transform the standard of care for cancer patients by delivering the next generation of innovative cancer treatments, and I look forward to collaborating with this talented team with the goal of bringing life-changing therapeutics to patients.\" Prior to joining Sutro, Dr. Borgman served as Vice President and Therapeutic Area Lead, Oncology, Hematology, and Transplant, at Jazz Pharmaceuticals, where she was responsible for global drug development for four marketed products and drug development plans for several emerging targets. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was responsible for the global development for cabozantinib and oversaw the development of multiple Phase 3 programs. She has also held leadership positions in Oncology Drug Development at KaloBios Pharmaceuticals, Talon Therapeutics (fo...